The recent licensing of a new meningococcal conjugate vaccine has prompted
government officials to expand recommended immunization practices. The new
vaccine is expected to drastically reduce the prevalence of invasive meningococcal
disease caused by Neisseria meningitidis serogroups
A, C, Y, and W-135, which make up the majority of cases in the United States.
The Advisory Committee on Immunization Practices to the Centers for
Disease Control and Prevention (CDC) recommended on February 10 that children
aged 11 and 12 years, teens entering high school, and college freshman living
in dormitories receive meningococcal (groups A, C, Y, and W-135) polysaccharide
diphtheria toxoid conjugate vaccine (Menactra). This vaccine, manufactured
by Sanofi Pasteur (Swiftwater, Pa), received US Food and Drug Administration
approval on January 14, 2005.
Mitka M. New Vaccine Should Ease Meningitis Fears. JAMA. 2005;293(12):1433-1434. doi:10.1001/jama.293.12.1433